Search details
1.
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
N Engl J Med
; 388(23): 2145-2158, 2023 06 08.
Article
in English
| MEDLINE | ID: mdl-36972026
2.
Diagnosing and staging epithelial ovarian cancer by serum glycoproteomic profiling.
Br J Cancer
; 130(10): 1716-1724, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38658783
3.
Molecular profiling of gestational trophoblastic neoplasia: Identifying therapeutic targets.
Gynecol Oncol
; 184: 111-116, 2024 Jan 31.
Article
in English
| MEDLINE | ID: mdl-38301309
4.
Differential outcomes and immune checkpoint inhibitor response among endometrial cancer patients with MLH1 hypermethylation versus MLH1 "Lynch-like" mismatch repair gene mutation.
Gynecol Oncol
; 177: 132-141, 2023 Oct.
Article
in English
| MEDLINE | ID: mdl-37683549
5.
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.
Gynecol Oncol
; 170: 300-308, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36758420
6.
TP53 mutation and abnormal p53 expression in endometrial cancer: Associations with race and outcomes.
Gynecol Oncol
; 178: 44-53, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37748270
7.
The Genomic Landscape of Vulvar Squamous Cell Carcinoma.
Int J Gynecol Pathol
; 42(5): 515-522, 2023 Sep 01.
Article
in English
| MEDLINE | ID: mdl-37131274
8.
ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer.
Future Oncol
; 19(23): 1577-1591, 2023 Jul.
Article
in English
| MEDLINE | ID: mdl-37334673
9.
Systematic mapping review of guidelines for BRCA1/2 genetic testing globally: investigating geographic and regional disparities in health equity for women and families at risk for hereditary ovarian cancer.
Int J Gynecol Cancer
; 33(2): 250-256, 2023 02 06.
Article
in English
| MEDLINE | ID: mdl-36368709
10.
Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutions.
Int J Gynecol Cancer
; 33(11): 1733-1742, 2023 11 06.
Article
in English
| MEDLINE | ID: mdl-37931976
11.
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.
Int J Gynecol Cancer
; 33(4): 562-570, 2023 04 03.
Article
in English
| MEDLINE | ID: mdl-36564099
12.
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.
N Engl J Med
; 381(20): 1929-1939, 2019 11 14.
Article
in English
| MEDLINE | ID: mdl-31722153
13.
Genomic profiling in low grade serous ovarian cancer: Identification of novel markers for disease diagnosis and therapy.
Gynecol Oncol
; 167(2): 306-313, 2022 11.
Article
in English
| MEDLINE | ID: mdl-36229265
14.
HER2 in Uterine Serous Carcinoma: Testing platforms and implications for targeted therapy.
Gynecol Oncol
; 167(2): 289-294, 2022 11.
Article
in English
| MEDLINE | ID: mdl-36114027
15.
What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer.
Gynecol Oncol
; 166(3): 410-416, 2022 09.
Article
in English
| MEDLINE | ID: mdl-35835612
16.
Is there a "low-risk" patient population in advanced epithelial ovarian cancer?: a critical analysis.
Am J Obstet Gynecol
; 227(5): 728-734, 2022 Nov.
Article
in English
| MEDLINE | ID: mdl-35640700
17.
Integrating Precision Medicine into the Contemporary Management of Gynecologic Cancers.
Curr Oncol Rep
; 24(7): 889-904, 2022 07.
Article
in English
| MEDLINE | ID: mdl-35347591
18.
Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.
Gynecol Oncol
; 163(3): 459-464, 2021 12.
Article
in English
| MEDLINE | ID: mdl-34702567
19.
Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer.
Gynecol Oncol
; 163(2): 254-261, 2021 11.
Article
in English
| MEDLINE | ID: mdl-34474927
20.
Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.
Gynecol Oncol
; 161(3): 676-680, 2021 06.
Article
in English
| MEDLINE | ID: mdl-33715892